Regulus (RGLS): Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi

Regulus (RGLS) tovar belgisi

Regulus Therapeutics (RGLS) aksiyalarining ushbu kotirovkalar grafigi RGLS8429 klinik sinovlarini kengaytirish orqali buyrak patologiyasi dori segmentida global yetakchilikka intilayotgan kompaniyaning dinamikasini aks ettiradi, bunda ko'rsatkich 0.02 darajasida turibdi. Uzoq muddatli laboratoriya kelishuvlari va komponentlar yetkazib berishning diversifikatsiyasi jarayon barqarorligini ta'minlaydi. Biznes miya va buyrak terapiyasi uchun hujayra ichidagi molekulalarni nishonga oluvchi ilg'or metodlarga asoslangan.

RGLS - Regulus Therapeutics, Inc. Uzoq muddatli qarzning o'z kapitaliga nisbati 04.07.2022 - 05.07.2025 oraligʻida

Regulus Therapeutics - tahliliy kesimlar va asosiy koʻrsatkichlar (RGLS)

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya kursi Regulus Therapeutics, Inc.|RGLS - Maqsadli narxlar grafigi
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor kapitallashuvi Regulus Therapeutics Inc.|RGLS - Korxona qiymati
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya hisobiga balans qiymati Regulus Therapeutics|RGLS - Kompaniyaning balans qiymati|Balans qiymatiga nisbatan bozor qiymati regulusrx.com|RGLS - Kompaniyaning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Qarzning kapitalga nisbati Regulus Therapeutics|RGLS - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli qarzdorlikning o'z kapitaliga nisbati regulusrx.com|RGLS - Kompaniyaning umumiy qarzi|Balans kapitallashuviga qarzlar Regulus Therapeutics Inc.
Kompaniyaning jamlanma tahlili:Regulus Therapeutics, Inc.
Regulus Therapeutics asosiy tovari

Regulus Therapeutics (RGLS) kompaniyasining operatsion barqarorligini ob'ektiv baholash uchun investorlarning uning qarz tuzilmasini kuzatib borishi muhimdir. Ushbu uzoq muddatli leveraj koeffitsiyenti bir yildan ortiq muddatga ega bo'lgan kreditlarning kapitalga nisbatini aks ettiradi. Ushbu koeffitsiyentning oshishi leverajning ortishi va destabilizatsiya xavflarini ko'rsatadi. Bu biotexnologiya sektori uchun juda muhimdir, chunki RNA terapiyasi ishlab chiqish sezilarli investitsiyalarni talab qiladi. Kompaniyaning strategik sherikliklari qarzga bog'liqlikni kamaytirishga yordam beradi va resurslar sinergiyasini ta'minlaydi.

Raqobatdosh kompaniyalar tahlili

Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi TEM|Uzoq muddatli qarzning o'z kapitaliga nisbati Qiagen Group QGEN|Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi Isis Pharmaceuticals (IONS)|Uzoq muddatli qarzning kapitalga nisbati RGEN (Repligen Corporation)|aviditybiosciences.com - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati CRISPR Therapeutics (CRSP)|WGS - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati RARE|Beam Tx (BEAM) - Uzoq muddatli majburiyatlarning kapitalga nisbati|Sarepta Therapeutics, Inc. - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzdorlikning o'z kapitaliga nisbati twistbioscience.com (TWST)|Uzoq muddatli qarzning o'z kapitaliga nisbati TXG|Uzoq muddatli qarzning kapitalga nisbati NTLA (Intellia Therapeutics Inc)|Uzoq muddatli qarzning o'z kapitaliga nisbati Stoke STOK|BLFS - Uzoq muddatli qarzning o'z kapitaliga nisbati|Wave Life Sciences - Uzoq muddatli qarzning o'z kapitaliga nisbati|MAZE: Uzoq muddatli qarzning kapitalga nisbati|Sionna Therapeutics - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzdorlikning kapitalga nisbati Prime Medicine Inc|TSHA - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga koeffitsiyenti uniQure Pharma (QURE)|Uzoq muddatli qarzning o'z kapitaliga nisbati MeiraGTx Holdings plc|Uzoq muddatli kreditlarning kapitalga nisbati regenxbio.com (RGNX)|Uzoq muddatli qarzning kapitalga nisbati Solid Biosciences|Uzoq muddatli qarzning kapitalga koeffitsiyenti Ocugen Inc OCGN|PACB (Pacific Biosciences of California) - Uzoq muddatli qarzning kapitalga nisbati|BNTC: Uzoq muddatli majburiyatlarning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Design Therapeutics DSGN|rocketpharma.com (RCKT) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|FDMT (4D Molecular Therapeutics, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning kapitalga nisbati LXEO|KRRO - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli majburiyatlarning o'z kapitaliga nisbati Editas Corp (EDIT)|SLN: Uzoq muddatli qarzning kapitalga nisbati|PRQR - Uzoq muddatli majburiyatlarning kapitalga nisbati|Codexis Bio - Uzoq muddatli qarzning o'z kapitaliga nisbati|Sangamo Therapeutics Inc. (SGMO) - Uzoq muddatli qarzning kapitalga nisbati|NAUT - Uzoq muddatli qarzning o'z kapitaliga nisbati|Metagenomi Therapeutics (MGX) - Uzoq muddatli kreditlarning kapitalga nisbati|DTIL: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzdorlikning kapitalga nisbati Generation Bio Corp|Uzoq muddatli qarzning kapitalga nisbati BOLD (Boundless Bio)|Uzoq muddatli qarzning o'z kapitaliga nisbati XCUR (exicuretx.com)|Uzoq muddatli qarzning o'z kapitaliga nisbati IMNN|Phio Pharmaceuticals Corp - Uzoq muddatli qarzdorlikning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Mustang Bio Corp (MBIO)|RNAZ - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati BNGO (bionanogenomics.com)|APDN (Applied DNA Sciences Inc) - Uzoq muddatli qarzdorlikning o'z kapitaliga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Bluebird Bio|Uzoq muddatli qarzning o'z kapitaliga nisbati IPA|OMGA (Omega Therapeutics) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzdorlikning kapitalga nisbati singulargenomics.com (OMIC)|SYRS - Uzoq muddatli qarzning kapitalga nisbati|Telesis Bio Inc. - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|TRACON (TCON) - Uzoq muddatli qarzning o'z kapitaliga nisbati|UBX - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi